Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 10, 2019 9:30 AM - Nov 12, 2019 5:40 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S08] Deep Dive into China Regulatory Reform from Various Perspective

Session Chair(s)

Ling  Su, PhD

Ling Su, PhD

Research Fellow

Shenyang Pharmaceutical University, Yeehong Business School, China

China regulatory reform has caused various changes in drug development in China. The drug development process has been shifted from conventional way to advanced way utilizing improved regulatory system for acceleration of innovative drug development. This session will cover recent regulatory environment for innovative drug and advanced therapy (gene therapy or cell therapy) by agency, and actual experience using new regulatory scheme by industry. Lastly, regulatory activities on intellectual proprietary protection which has been engaged by NMPA is also presented as a hot topic.


Xiaofang  Cheng

Introduction to the Revision of the Drug Administration Law

Xiaofang Cheng

National Medical Products Administration (NMPA), China

Principal Staff, Department of Policies and Regulations

Jianchao  Gao

Overview Requirements for Advanced Therapies Review

Jianchao Gao

Center for Drug Evaluation, NMPA , China

Senior ReviewerBiological Department

Fei  Xu

Introduction to Overseas Inspection of Chinese Drugs

Fei Xu

National Medical Products Administration (NMPA), China

Engineer, Center for Food and Drug Inspection of NMPA

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.